Immune Checkpoint Inhibitors to Treat Malignant Lymphomas

Table 3

Clinical efficacy of checkpoint inhibitors in other hematologic malignancies.

Drug	Ph	Target	Disease	N	ORR (%)	CR (%)	PR (%)	SD (%)	OS	PFS	Ref
Pembrolizumab	I	Anti-PD-1	PMBCL	19	44	11	33		NR		24
Pembrolizumab	II	Anti-PD-1	DLBCL	66	51	34	17	37	NR	16 m, 70%	27
Ipilimumab	I	Anti-CTLA-4	NHL	18	11	5.5	5.5				30

Ph: phase; N: number of patients; m: month; ORR: overall response rate; CR: complete response; PR: partial response; SD: stable disease; OS: overall response; PFS: progression-free survival; Ref: reference; BV: brentuximab vedotin; NR: not reached.